EQ - Equillium Inc Stock Price, Fair Value and News

$0.67-0.05 (-6.94%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

EQ Price Action

Last 7 days

-6.5%

Last 30 days

-4%

Last 90 days

-26.5%

Trailing 12 Months

46.9%

EQ RSI Chart

EQ Valuation

Market Cap

25.5M

Price/Earnings (Trailing)

-5.53

Price/Sales (Trailing)

0.56

EV/EBITDA

-1.11

Price/Free Cashflow

-1.19

EQ Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EQ Fundamentals

EQ Revenue

Revenue (TTM)

45.9M

Rev. Growth (Yr)

37.1%

Rev. Growth (Qtr)

-12.21%

EQ Earnings

Earnings (TTM)

-4.6M

Earnings Growth (Yr)

99.81%

Earnings Growth (Qtr)

-101.5%

EQ Profitability

EBT Margin

-25.28%

Return on Equity

-19.91%

Return on Assets

-13.39%

Free Cashflow Yield

-84.31%

EQ Investor Care

Shares Dilution (1Y)

0.89%

Diluted EPS (TTM)

-0.13

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	37.9M	42.6M	45.9M	0
2023	20.8M	25.9M	31.0M	36.1M
2022	0	0	0	15.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Equillium Inc

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.

CEO	Mr. Bruce D. Steel C.F.A.
WEBSITE	https://equilliumbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	47

Equillium Inc Frequently Asked Questions

What is the ticker symbol for Equillium Inc? What does EQ stand for in stocks?

EQ is the stock ticker symbol of Equillium Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Equillium Inc (EQ)?

As of Wed Dec 04 2024, market cap of Equillium Inc is 25.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EQ stock?

You can check EQ's fair value in chart for subscribers.

Is Equillium Inc a good stock to buy?

The fair value guage provides a quick view whether EQ is over valued or under valued. Whether Equillium Inc is cheap or expensive depends on the assumptions which impact Equillium Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EQ.

What is Equillium Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 04 2024, EQ's PE ratio (Price to Earnings) is -5.53 and Price to Sales (PS) ratio is 0.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EQ PE ratio will change depending on the future growth rate expectations of investors.